DATATRAK Awarded First Study With Kreara Solutions

Dermatology Division of a Global Enterprise to conduct a Phase II study in Japan with DATATRAK and Kreara providing eClinical and Data Management Services
CLEVELAND, March 8, 2011 /PRNewswire/-- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded its first study by Kreara Solutions, a Contract Research Organization (CRO) in India, with which the Company had partnered in 2010. Both companies will work together in order to execute a Phase II study for the Dermatology Division of a Global Enterprise, whose core competencies include the fields of Health Care, Nutrition and High-Tech Materials. 

The trial will be conducted in Japan and employ several CROs based in Japan, India and the USA to conduct project management, monitoring, data management and other study-specific services. All of the CROs, as well as the Sponsor, will be utilizing DATATRAK eClinicalTM for Electronic Data Capture (EDC) and Medical Coding.

Anoop P. Ambika, Kreara's CEO and Managing Director said, "Kreara has always strived to provide quality and timely data management services to its clients in adherence to the internal standards and standards set by the client and regulatory bodies. Kreara looks forward to working closely with DATATRAK to deliver the challenging requirements of this trial, all the while adhering to the cost, quality and timeliness as envisioned during the planning phase."

"DATATRAK's unified eClinical platform is an ideal solution for studies which intend to employ multiple CROs from various geographic locations around the world," said Laurence P. Birch, DATATRAK's Chairman and CEO.  "We can help companies to streamline their study communications, provide a single point of access for all study users, and enable both the Sponsor and CROs to gain real-time access to patient data. We are excited to embark on this first study with Kreara, especially as we guide them through the design and deployment of their study as an Enterprise Transfer client."

About Kreara Solutions

KREARA Solutions is a clinical data management and biometrics solution provider based out of the beautiful campus of Technopark Trivandrum, Kerala in India. Kreara was established in April 2004 as a private limited company with the intention of providing quality services for the clinical research, life sciences and financial markets. Kreara has grown into a leading Clinical Research Organization that specializes in providing data management, statistical and software solutions for the process of clinical drug development. Having grown into one of the most trusted partners for some of the life sciences companies across the globe, Kreara has worked with clients from Europe, USA and Japan. For more information on Kreara, please visit http://www.kreara.com.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinicalTM software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 67 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit http://www.datatrak.net.

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

Combining an anti-TREM2 antibody with an immuno-oncology drug that blocks PD-1 led to complete tumor control in a mouse study.